BACKGROUND INFORMATION ON THE PROCEDURE 
1. 
Submission of the dossier 
The company Bayer AG submitted on 28 December 2001 an application for Marketing Authorisation 
to  the  European  Agency  for  the  Evaluation  of  Medicinal  Products  (EMEA)  for  Levitra,  through  the 
centralised  procedure.  After  agreement  by  the  CPMP  on  31  May  2001,  this  medicinal  product  has 
been referred to Part B of the Annex to Council Regulation No (EEC) 2309/93 of 22 July 1993. 
The Rapporteur and Co-Rapporteur appointed by the CPMP were: 
Rapporteur: 
            Gonzalo Calvo Rojas 
Co-Rapporteur:  Barbara van Zwieten-Boot 
Licensing status: 
The product was not licensed in any country at the time of submission of the application. 
2. 
• 
• 
• 
• 
• 
• 
• 
Steps taken for the assessment of the product 
The procedure started on 28 January 2002. 
The  Rapporteur's  first  assessment  report  was  circulated  to  all  CPMP  Members  on  12  April 
2002. The Co-Rapporteur's first assessment report was circulated to all CPMP Members on 10 
April 2002. 
During the meeting on 28-30 May 2002 the CPMP agreed on the consolidated list of questions 
to be sent to the company. The final consolidated list of questions was sent to the company on 
31 May 2002. 
The  company  submitted  the  responses  to  the  consolidated  list  of  questions  on  13  September 
2002. 
The  Rapporteur  and  Co-Rapporteur  circulated  the  response  Assessment  Report  on  the 
company’s responses to the list of questions to all CPMP Members on 21 October 2002. 
During  the  meeting  on  19-21  November  2002  the  CPMP,  in  the  light  of  the  overall  data 
submitted  and  the  scientific  discussion  within  the  Committee,  issued  a  positive  opinion  for 
granting a Marketing Authorisation to Bayer AG on 21 November 2002. 
The  CPMP  opinions  were  forwarded,  in  all  official  languages  of  the  European  Union,  to  the 
European Commission, which adopted the corresponding Decisions on 6 March 2003. 
1/1 
EMEA 2005 
 
 
 
 
 
 
 
 
 
